Superluminal Medicines Announces Collaboration With Eli Lilly And Company To Advance Small Molecule Therapeutics For Cardiometabolic Diseases And Obesity
Reuters
Aug 14
Aug 14 (Reuters) - Eli Lilly and Co :: *SUPERLUMINAL MEDICINES ANNOUNCES COLLABORATION WITH ELI LILLY AND COMPANY TO ADVANCE SMALL MOLECULE THERAPEUTICS FOR CARDIOMETABOLIC DISEASES AND OBESITY *SUPERLUMINAL MEDICINES: ELIGIBLE TO RECEIVE UP TO $1.3 BILLION *SUPERLUMINAL MEDICINES: LILLY TO RECEIVE EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALIZE COMPOUNDS FROM COLLABORATION AFTER PREDEFINED CRITERIA IS MET
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.